It was ruled that the state did not have the power to overrule the FDA’s approval of a drug. However, Governor Deval Patrick was given a chance to respond with controls to monitor the prescribing and use of the drug. The state Board of Registration in Medicine approved a restriction that physicians must complete a risk assessment and pain management treatment agreement with patients before prescribing Zohydro. The agreement includes monitoring of prescribed number of pills and other conditions the prescriber may find appropriate. In addition, a state executive order will require prescribers to participate in the Prescription Monitoring Program to detect possible misuse. Additional controls may be implanted by other Massachusetts agencies. What are your own thoughts on Zohydro’s ban and the recent judgment?
For additional information, please see the article in the Boston Globe.
Image courtesy of [cooldesign]/FreeDigitalPhotos.Net